Skip to main content

News

This Week is #MedSafetyWeek 2022

Last Updated:

November 7th to 13th is #MedSafetyWeek - do you know how to report a side effect from medication?

Rivotril - Further shortage

Last Updated:

Epilepsy Ireland has been notified by the Health Products Regulatory Authority (HPRA) that further issues are expected with the supply of the Anti-Seizure medication, Rivotril (Clonazepam).

In September, manufacturing issues created a shortage of the medication and led to difficulties for many patients in having their prescriptions filled. Although supply had returned to normal in recent weeks, it now appears that further shortages are likely.

Notice on Anti-Seizure Medication Vimpat (Lacosamide)

Last Updated:

Epilepsy Ireland have been contacted by UCB, manufacturers of the Anti-Seizure Medication Vimpat (Lacosamide), informing us that their patent exclusivity for the medication has now expired.

This means that other pharmaceutical manufacturers can bring forward generic versions of this medication to be marketed in Ireland.

NCPE issue positive recommendation on reimbursement of Cenobamate (Ontozry®)

Last Updated:

The National Centre for Pharmacoeconomics (NCPE) have updated Epilepsy Ireland that they have issued a positive recommendation regarding the potential reimbursement of the anti-seizure medication, Cenobamate.

The medication has been indicated for use in adults living with focal-onset seizures and has posted positive clinical trial results. Epilepsy Ireland made a submission to the NCPE in July supporting reimbursement of the medication.